author

Dr. Ajit Jha

Lifetime Member of Indian Medical Association and Editorial Board Member at International Journal of Diabetes and Endocrinology, with over 20 years of experience in healthcare consulting, health promotion, and medical education. Dedicated to empowering individuals and organizations through effective healthcare strategies, public health awareness, and patient-focused initiatives. Skilled in healthcare consulting, health education, and organizational guidance, with a strong commitment to improving patient outcomes and supporting institutions in navigating the evolving healthcare landscape through practical, experience-driven solutions.

Ozempic and Wegovy Are Surprising Doctors: New Research Shows Benefits Beyond Weight Loss

Everyone knows Ozempic and Wegovy for one reason: weight loss. But in 2026, a wave of new research is revealing something that is catching even doctors off guard. These GLP-1 receptor agonist drugs are doing far more than shrinking waistlines – they are reducing migraines, lowering blood pressure, protecting the heart, and now showing promise […]

Weight Loss Surgery Is Down 25%: Why GLP-1 Drugs Are Taking Over and What Experts Want You to Know

Weight loss surgery dominated obesity treatment for over two decades. Surgeons could not keep up with demand. Hospital waiting lists stretched months long. Then, almost overnight, the operating rooms started getting quieter. The reason is sitting in millions of medicine cabinets. GLP-1 drugs — Ozempic, Wegovy, Mounjaro, Zepbound — have surged so dramatically that bariatric […]